Omeros(OMER),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

OMER Omeros

Market Closed 01-09 16:00:00 EST

12.49

-0.96

-7.14%

盘后12.61

+0.12+0.96%

19:59 EST

High14.25	Low12.45	Vol4.59M
Open13.66	D1 Closing13.45	Amplitude13.38%
Mkt Cap885.55M	Tradable Cap806.24M	Total Shares70.90M
T/O59.44M	T/O Rate7.11%	Tradable Shares64.55M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"OMER","market":"US","secType":"STK","nameCN":"Omeros","latestPrice":12.49,"timestamp":1767992400000,"preClose":13.45,"halted":0,"volume":4588809,"hourTrading":{"tag":"盘后","latestPrice":12.61,"preClose":12.49,"latestTime":"19:59 EST","volume":83774,"amount":1050312.0008,"timestamp":1768006797135},"delay":0,"floatShares":64550800,"shares":70900459,"eps":-2.009792,"marketStatus":"Market Closed","change":-0.96,"latestTime":"01-09 16:00:00 EST","open":13.66,"high":14.25,"low":12.45,"amount":59435506.912857,"amplitude":0.133829,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.009792,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768208400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1254974400000,"exchange":"NASDAQ","adjPreClose":13.45,"preHourTrading":{"tag":"盘前","latestPrice":13.59,"preClose":13.45,"latestTime":"09:28 EST","volume":19063,"amount":260396.653022,"timestamp":1767968889002},"postHourTrading":{"tag":"盘后","latestPrice":12.61,"preClose":12.49,"latestTime":"19:59 EST","volume":83774,"amount":1050312.0008,"timestamp":1768006797135},"volumeRatio":1.1237380997834472,"impliedVol":1.0106,"impliedVolPercentile":0.4861},"requestUrl":"/m/hq/s/OMER/tweets","defaultTab":"tweets","newsList":[{"id":"2601836043","title":"Omeros (OMER) Receives a Buy from WBB Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2601836043","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601836043?lang=en_us&edition=fundamental","pubTime":"2026-01-08 22:15","pubTimestamp":1767881750,"startTime":"0","endTime":"0","summary":"In a report released today, Stephen Brozak from WBB Securities maintained a Buy rating on Omeros, with a price target of $55.00. According to TipRa...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/omeros-omer-receives-a-buy-from-wbb-securities-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/omeros-omer-receives-a-buy-from-wbb-securities-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","OMER"],"gpt_icon":0},{"id":"2601364007","title":"Omeros Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2601364007","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601364007?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:19","pubTimestamp":1767878340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OMER/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 08, 2026 08:19 ET (13:19 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OMER"],"gpt_icon":0},{"id":"2601369150","title":"Balanced Risk/Reward and Gradual Yartemlea Ramp Justify Hold Rating on Omeros","url":"https://stock-news.laohu8.com/highlight/detail?id=2601369150","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601369150?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:15","pubTimestamp":1767874551,"startTime":"0","endTime":"0","summary":"Needham analyst Serge Belanger has maintained their neutral stance on OMER stock, giving a Hold rating on December 30. Serge Belanger has given his...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/balanced-risk-reward-and-gradual-yartemlea-ramp-justify-hold-rating-on-omeros-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/balanced-risk-reward-and-gradual-yartemlea-ramp-justify-hold-rating-on-omeros-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OMER"],"gpt_icon":0},{"id":"2601336301","title":"Omeros price target raised to $40 from $20 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2601336301","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601336301?lang=en_us&edition=fundamental","pubTime":"2026-01-08 19:11","pubTimestamp":1767870695,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Brandon Folkes raised the firm’s price target on Omeros (OMER) to $40 from $20 and keeps a Buy rating on the shares. The fi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/omeros-price-target-raised-to-40-from-20-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/omeros-price-target-raised-to-40-from-20-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OMER"],"gpt_icon":0},{"id":"2601363931","title":"Omeros Corporation : H.c. Wainwright Raises Target Price to $40 From $20","url":"https://stock-news.laohu8.com/highlight/detail?id=2601363931","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601363931?lang=en_us&edition=fundamental","pubTime":"2026-01-08 19:06","pubTimestamp":1767870395,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nAZN4RSH1A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OMER","BK4007"],"gpt_icon":0},{"id":"2600657340","title":"Exchange-Traded Funds, Equity Futures Higher Ahead of First Trading Day of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2600657340","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600657340?lang=en_us&edition=fundamental","pubTime":"2026-01-02 21:46","pubTimestamp":1767361595,"startTime":"0","endTime":"0","summary":"The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.6%, and the actively traded Invesco QQQ Trust (QQQ) advanced 1% in Friday's premarket activity ahead of the first trading da","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RTH.AU","VHT.AU","XLI","SOC","SOXX","BITF","EETH","XSD","BETH","XRT","XLV","RTH","EEM","SPY.AU","VHT","XLP","VDC","IYW","FAS","SPY","IYH","EQR","XLK","IVV","PMR","IGM",".DJI","VIS","FAZ","IBB","IYK","XLF","QQQ","UNG","XLY","XLE","EXI","OMER","SOC.AU","BITO","IYE","IYJ"],"gpt_icon":1},{"id":"2600065161","title":"Sector Update: Health Care Stocks Mixed Pre-Bell Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=2600065161","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600065161?lang=en_us&edition=fundamental","pubTime":"2026-01-02 21:29","pubTimestamp":1767360585,"startTime":"0","endTime":"0","summary":"Health care stocks were mixed premarket Friday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.1% and the iShares Biotechnology ETF (IBB) flat.Omeros (OMER) stock was up 4.4% premarket after closing the previous session with a 1.3% rise.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LABU","BK4135","LU1883839398.USD","IE00B64PRP62.GBP","LU1894683264.USD","STT","LU0061475181.USD","BK4007","IE0034235188.USD","XLV","XBI","LU1894683348.USD","BK4550","BK4585","IE00B3QW5Z07.USD","IBB","OMER","BK4588","BK4581","FDN","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2600708537","title":"The Year-End 2025 Biotech Rally And What It Means For 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2600708537","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600708537?lang=en_us&edition=fundamental","pubTime":"2025-12-31 23:54","pubTimestamp":1767196440,"startTime":"0","endTime":"0","summary":"Biotechnology stocks are wrapping up 2025 on a high note, bouncing back from a rocky start to deliver some of the year’s most impressive gains. What began as a sector weighed down by tariff fears and political noise has transformed into one of the market’s standout performers, powered by deal making, drug approvals, and breakthrough clinical results. The big question heading into 2026 is simple: can this momentum last?The performance metrics speak volumes. The iShares Biotechnology ETF  has climbed 29.51% year to date through December 29, while the State Street SPDR S&P Biotech ETF  has done even better with gains around 35.84%. The Nasdaq Biotechnology Index sits at 5,766.59, marking a 34% jump for the year.Regulatory wins provided another boost. The FDA greenlit 44 new therapies in 2025, with 26 approvals coming in the second half alone. December saw notable wins including Cytokinetics Incorporated’s  Myqorzo for a heart condition, marking the company’s first approval after 27 years ","market":"us","thumbnail":"/next-assets/images/benzinga-post-card-placeholder.svg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["/next-assets/images/benzinga-post-card-placeholder.svg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/25/12/49650052/the-year-end-2025-biotech-rally-and-what-it-means-for-2026","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/25/12/49650052/the-year-end-2025-biotech-rally-and-what-it-means-for-2026","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LU2063271972.USD","LU2592432038.USD","LU0256863811.USD","SG9999014880.SGD","NVIW.SI","CYTK","QID","MRK","USAW.SI","IE00BJT1NW94.SGD","VRNA","IE00B1BXHZ80.USD","NQmain","LU1037948897.HKD","LU0823434740.USD","GPCR","BK4581","LU1935042991.SGD","OMER","LU1116320737.USD","IE00BBT3K403.USD","LU0306807586.USD","BK4532","IE00BVYPNW00.USD","LU0471298694.HKD","NVS","TQQQ","JNJ","RNA","SQQQ","LU2089984988.USD","USJW.SI","IONS","IE0005OL40V9.USD",".IXIC","MNQmain","SG9999014906.USD","TSYW.SI","ITCI","LU2430703178.SGD","PSQ","QLD","IBB","EYPT","LU0432979614.USD","MNPR","PFE","BK4505"],"gpt_icon":1},{"id":"2594494299","title":"Biohaven, Omeros And Other Big Stocks Moving Lower In Friday's Pre-Market Session","url":"https://stock-news.laohu8.com/highlight/detail?id=2594494299","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2594494299?lang=en_us&edition=fundamental","pubTime":"2025-12-26 21:03","pubTimestamp":1766754180,"startTime":"0","endTime":"0","summary":"U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Friday.Shares of Biohaven Ltd  fell sharply in pre-market trading after the company reported that its Phase 2 depression drug trial missed its primary endpoint.The biopharmaceutical company announced BHV-7000, an investigational drug for major depressive disorder, failed to achieve a reduction in depressive symptoms versus placebo in the six-week study, measured by the Montgomery sberg Depression Rating Scale.Biohaven shares dipped 14.3% to $9.27 in pre-market trading.Here are some other stocks moving lower in pre-market trading.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/26/Display-Of-Stock-Market-Quotes.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/26/Display-Of-Stock-Market-Quotes.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/25/12/49592180/biohaven-omeros-and-other-big-stocks-moving-lower-in-fridays-pre-market-session","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/25/12/49592180/biohaven-omeros-and-other-big-stocks-moving-lower-in-fridays-pre-market-session","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BHVN","BK4139","LU1093756325.SGD","LU1093756168.USD","BK4007","OMER"],"gpt_icon":0},{"id":"2594128665","title":"Nike, Omeros Corporation, Micron Technology, Intel And Dynavax Technologies: Why These 5 Stocks Are On Investors' Radars Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2594128665","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2594128665?lang=en_us&edition=fundamental","pubTime":"2025-12-25 09:49","pubTimestamp":1766627340,"startTime":"0","endTime":"0","summary":"The Dow Jones Industrial Average climbed 0.6% to 48,731.16, while the S&P 500 added 0.32% to close at 6,932.05.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/24/Stock-Market-Trading-Graph-And-Financial.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/24/Stock-Market-Trading-Graph-And-Financial.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/equities/25/12/49588564/nike-omeros-corporation-micron-technology-intel-and-dynavax-technologies-why-these-5-stocks-are-on-investors-radars-today","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/25/12/49588564/nike-omeros-corporation-micron-technology-intel-and-dynavax-technologies-why-these-5-stocks-are-on-investors-radars-today","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LU2089985449.USD","LU2286300806.USD","IE00BYQQ9H92.USD","LU0786609619.USD","LU0157215616.USD","LU1267930573.SGD","LU2360106780.USD","BK4532","LU2543165471.USD","LU1366333091.USD","LU1323610961.USD","BK4566","BK4527","LU1852331112.SGD","BK4553","OMER","INTC","LU0029864427.USD","LU0082616367.USD","LU0274383776.USD","04335","LU1316542783.SGD","LU2048586759.USD","BK4535","BK4543","BK4602","LU0719512351.SGD","LU0203347892.USD","BK4605","LU0889566641.SGD","LU0310800379.SGD","BK4534","BK4007","LU0321505439.SGD","GB00BDT5M118.USD","LU0642271901.SGD","IE00B19Z3581.USD","BK4211","LU0792757196.USD","LU2931357623.SGD","BK4141","LU2211815571.USD","LU2148611432.USD","LU0128525929.USD","LU1303367103.USD","LU2250418816.HKD","LU0823411888.USD","MU","IE00BFXG0V08.USD","BK4550","NKE","LU0708994859.HKD","BK4612","BK4533","LU0081259029.USD","BK4579","BK4558","BK4512","LU0056508442.USD","BK4581","BK4585","LU2098885051.SGD","LU0127658192.USD","BK4529","LU0203345920.USD","IE00B7SZLL34.SGD","LU0321505868.SGD","BK4139","BK4515","BK4554","BK4575","LU0097036916.USD","IE0002270589.USD","IE00B19Z3B42.SGD","LU1267930813.SGD","BK4146","DVAX","BK4561","BK4588"],"gpt_icon":1},{"id":"2594888632","title":"Analysts Are Neutral on Top Healthcare Stocks: Biohaven Ltd. (BHVN), Omeros (OMER)","url":"https://stock-news.laohu8.com/highlight/detail?id=2594888632","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2594888632?lang=en_us&edition=fundamental","pubTime":"2025-12-25 05:40","pubTimestamp":1766612406,"startTime":"0","endTime":"0","summary":"Analysts fell to the sidelines weighing in on Biohaven Ltd. (BHVN – Research Report) and Omeros (OMER – Research Report) with neutral ratings, indi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-neutral-on-top-healthcare-stocks-biohaven-ltd-bhvn-omeros-omer-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-neutral-on-top-healthcare-stocks-biohaven-ltd-bhvn-omeros-omer-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","OMER","BHVN","HCSG"],"gpt_icon":0},{"id":"2594740666","title":"BUZZ-U.S. STOCKS ON THE MOVE-Snowflake, Hecla Mining, Newmont","url":"https://stock-news.laohu8.com/highlight/detail?id=2594740666","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2594740666?lang=en_us&edition=fundamental","pubTime":"2025-12-25 01:35","pubTimestamp":1766597701,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Snowflake, Hecla Mining, NewmontEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: h","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251224:nL6N3XU0K9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVDY","AGRZ","2NVD.UK","OMER","NVD2.UK","NVDD","TSE","MNSH","NVDS","NVD","NVD3.UK","CDE","NVDS.UK","PCLA","LU2089283258.USD","ZKH","NVDU","LU1791710400.SGD","CCL.UK","NEM","LU0056508442.USD","LU2087625088.SGD","BK4533","UP","DDOG","HL","NINE","SPCE","LU0823434583.USD","WOK","3NVD.UK","SNVD.UK","LU0788109121.HKD","DVAX","LU1037948897.HKD","FMFC","BK4007","SNOW","IE00BD6J9T35.USD","NVIW.SI","CCL","LU0494093205.USD","SOBR","VRTX"],"gpt_icon":1},{"id":"2594406333","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2594406333","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2594406333?lang=en_us&edition=fundamental","pubTime":"2025-12-25 01:22","pubTimestamp":1766596978,"startTime":"0","endTime":"0","summary":"Omeros  said Wednesday the US Food and Drug Administration has approved Yartemlea to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy, a complication of stem-cell transplants.Shares of the healthcare firm increased nearly 80% as intraday trading volume jumped to nearly 20.7 million, versus a daily average of roughly 3.7 million.Edgewise Therapeutics  rose roughly 21% after the company said it completed parts B and C of a phase 2 trial of EDG-7500 in patients with obstructive and nonobstructive hypertrophic cardiomyopathy and reported favorable interim safety results from its ongoing part D study.Trading volume rose to 2.5 million from a daily average of about 1.3 million.Sanofi  on Wednesday agreed to buy infectious disease vaccine maker Dynavax Technologies  in a deal with an equity value of about $2.2 billion, as the company aims to strengthen its adult immunization portfolio.Shares of Dynavax Technologies gained about 38% as intraday trading volume clim","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4081","BK4139","OMER","BK4539","SNY","BK4585","EWTX","BK4588","DVAX","BK4007","DYNA","IE00BFXG1179.USD"],"gpt_icon":0},{"id":"2594052654","title":"Omeros Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2594052654","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2594052654?lang=en_us&edition=fundamental","pubTime":"2025-12-25 01:05","pubTimestamp":1766595900,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OMER/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 24, 2025 12:05 ET (17:05 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OMER"],"gpt_icon":0},{"id":"2594940514","title":"Omeros Shares Surge on FDA Approval For Yartemlea","url":"https://stock-news.laohu8.com/highlight/detail?id=2594940514","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2594940514?lang=en_us&edition=fundamental","pubTime":"2025-12-25 00:55","pubTimestamp":1766595300,"startTime":"0","endTime":"0","summary":"Shares of Omeros surged after the pharmaceutical company received Food and Drug Administration approval for its Yartemlea treatment.The stock was up 78% to $15.60 on Wednesday and was briefly paused for volatility. Shares have risen 56% this year.The Seattle-based pharmaceutical company said Wednesday that the FDA greenlit Yartemlea for patients ages 2 and older who experience a serious complication from stem-cell transplant procedures.The FDA approval makes Yartemlea the only approved treatment that works by inhibiting the effector enzyme of the lectin pathway, Omeros said. It said it is finalizing preparations for a product launch in the U.S. next month.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Omeros Shares Surge on FDA Approval For Yartemlea","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","OMER"],"gpt_icon":0},{"id":"2593403318","title":"Dow Gains Over 100 Points; US Jobless Claims Decline","url":"https://stock-news.laohu8.com/highlight/detail?id=2593403318","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593403318?lang=en_us&edition=fundamental","pubTime":"2025-12-24 23:27","pubTimestamp":1766590067,"startTime":"0","endTime":"0","summary":" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"73197d9df2f4cf43e87414d936fef4c7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/market-summary/25/12/49583720/dow-gains-over-100-points-us-jobless-claims-decline","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTXR","OMER","USAW.SI","BK4007","QLD",".IXIC","PCLA","USJW.SI","BK4157","TQQQ","BK4170","SQQQ","MNQmain","NQmain","BK4104","BK4122","MWG","PCOM","TSYW.SI","QID","SOBR","NVIW.SI","SONM","BK4020","PSQ"],"gpt_icon":1},{"id":"2593640874","title":"Omeros Shares Rise 81.7% After US FDA Approves Co's Drug to Treat Dangerous Transplant Complication","url":"https://stock-news.laohu8.com/highlight/detail?id=2593640874","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593640874?lang=en_us&edition=fundamental","pubTime":"2025-12-24 23:15","pubTimestamp":1766589337,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251224:nFWN3XT0RR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","OMER"],"gpt_icon":0},{"id":"2593470865","title":"BRIEF-FDA Approves Omeros’ YARTEMLEA","url":"https://stock-news.laohu8.com/highlight/detail?id=2593470865","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593470865?lang=en_us&edition=fundamental","pubTime":"2025-12-24 22:05","pubTimestamp":1766585106,"startTime":"0","endTime":"0","summary":"BRIEF-FDA Approves Omeros’ YARTEMLEADec 24 (Reuters) - Omeros Corp OMER.O:FDA APPROVES OMEROS’ YARTEMLEA – FIRST AND ONLY THERAPY INDICATED FOR TA-TMAOMEROS CORP - PLANS U.S. PRODUCT LAUNCH OF YARTEML","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251224:nTUA4XMX13:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OMER","BK4007"],"gpt_icon":0},{"id":"2593770304","title":"US FDA approves Omeros' drug to treat dangerous transplant complication","url":"https://stock-news.laohu8.com/highlight/detail?id=2593770304","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593770304?lang=en_us&edition=fundamental","pubTime":"2025-12-24 22:01","pubTimestamp":1766584917,"startTime":"0","endTime":"0","summary":"US FDA approves Omeros' drug to treat dangerous transplant complicationDec 24 (Reuters) - The U.S. Food and Drug Administration has approved Omeros' OMER.O drug for a dangerous transplant complication","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251224:nL4N3XU0K2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OMER","BK4007"],"gpt_icon":0},{"id":"2593477703","title":"FDA Approves Omeros' YARTEMLEA for TA-TMA Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2593477703","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593477703?lang=en_us&edition=fundamental","pubTime":"2025-12-24 22:00","pubTimestamp":1766584830,"startTime":"0","endTime":"0","summary":"Omeros Corporation announced that the U.S. Food and Drug Administration  has approved YARTEMLEA  for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy . YARTEMLEA is the first and only FDA-approved therapy for this often-fatal complication and is indicated for use in both adults and children aged two years and older. The approval follows strong efficacy and safety data, with a U.S. product launch planned for January 2026. No grant or funding from multiple organizations was mentioned.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Omeros Corporation published the original content used to generate this news brief via Business Wire  on December 24, 2025, and is solely responsible for the information","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251224:nNDL5qJqmJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OMER","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.omeros.com","stockEarnings":[{"period":"1week","weight":-0.2375},{"period":"1month","weight":0.1112},{"period":"3month","weight":1.9809},{"period":"6month","weight":2.4219},{"period":"1year","weight":0.2629},{"period":"ytd","weight":-0.2728}],"compareEarnings":[{"period":"1week","weight":0.016},{"period":"1month","weight":0.0095},{"period":"3month","weight":0.0629},{"period":"6month","weight":0.113},{"period":"1year","weight":0.1774},{"period":"ytd","weight":0.0178}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that is in phase Ib clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders; and OMS405 that is in phase II clinical trials for opioid and nicotine addiction. In addition, the company develops MASP-2-small-molecule inhibitors for the treatment of aHUS, HSCT-TMA, and age-related macular degeneration; GPR174 inhibitors and chimeric antigen receptor T-Cell and adoptive T-Cell therapies for various cancers; and G protein-coupled receptors for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.","yearOnYearQuotes":[{"month":1,"riseRate":0.352941,"avgChangeRate":-0.009999},{"month":2,"riseRate":0.5625,"avgChangeRate":0.058594},{"month":3,"riseRate":0.625,"avgChangeRate":0.097428},{"month":4,"riseRate":0.375,"avgChangeRate":-0.031657},{"month":5,"riseRate":0.375,"avgChangeRate":-0.032445},{"month":6,"riseRate":0.3125,"avgChangeRate":0.036171},{"month":7,"riseRate":0.4375,"avgChangeRate":0.065457},{"month":8,"riseRate":0.3125,"avgChangeRate":-0.029297},{"month":9,"riseRate":0.3125,"avgChangeRate":-0.001727},{"month":10,"riseRate":0.5,"avgChangeRate":-0.042054},{"month":11,"riseRate":0.647059,"avgChangeRate":0.236058},{"month":12,"riseRate":0.529412,"avgChangeRate":0.065706}],"exchange":"NASDAQ","name":"Omeros","nameEN":"Omeros"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Omeros(OMER),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Omeros(OMER) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Omeros,OMER,Omeros股票,Omeros股票老虎,Omeros股票老虎国际,Omeros行情,Omeros股票行情,Omeros股价,Omeros股市,Omeros股票价格,Omeros股票交易,Omeros股票购买,Omeros股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Omeros(OMER),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Omeros(OMER) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}